TLRY

Over the past six months, Tilray Brands' stock (TLRY) has experienced a significant decline, with a 1-year change of -65.89% and a 3-month change of -7.84% as of September 22, 2026. The share price as of September 18, 2026, was $4.00, a decline of 66.98% from $12.10 on September 19, 2025. Key events impacting the stock include earnings reports, with the company holding its Fourth Quarter 2026 Earnings Call on July 28, 2026, and its Third Quarter 2026 Earnings Call on April 1, 2026, reporting a significant earnings per share (EPS) miss for its fiscal fourth quarter 2026 despite record revenue and adjusted EBITDA for the fiscal year. Analyst ratings have varied, with some analysts trimming fair value estimates and price targets due to slower international cannabis permit timing and more cautious beverage expectations. Strategic acquisitions and partnerships include the acquisition of BrewDog between March and April 2026, an exclusive license with Carlsberg Group in February 2026 for U.S. beer distribution starting in 2027, the purchase of Lyphe Group in April 2026 to expand medical cannabis services in the UK, and a major expansion of global medical cannabis cultivation announced in August 2026, increasing total annual production capacity to approximately 275 metric tonnes. The stock's performance has also been influenced by broader market trends and discussions around cannabis stocks, including speculation about U.S. cannabis rescheduling.